Open Live Account
BEST TRADING FOR RECIVE REBATE
Login

(Reuters) – The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline’s (L:GSK) experimental treatment for a common form of blood cancer.

GSK’s belantamab mafodotin, or BLENREP, was approved for treating adults with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, the drugmaker said in a statement.

Multiple myeloma is the second most common form of blood cancer in the U.S. and is generally considered treatable, but not curable.

A U.S. FDA panel had earlier raised safety concerns about the drug causing deposits to gather on the cornea in the eyes, but later voted in its favor saying the benefits of the treatment outweigh the risks.

Approval for belantamab mafodotin, a rival to Johnson & Johnson (N:JNJ) and Genmab ‘s (CO:GMAB) Darzalex treatment, is seen as important for GSK’s growing oncology portfolio.

Last month, a panel of the European Medicines Agency (EMA) also recommended approving the drug.

Source : https://th.investing.com

Legal: This website is operated by TRBHInternational Limited
Trading Rebate Broker is the TRBHInternational Limited , Room 2204,299QRC, 287-299 Queen’s Rond,Central
TRBHInternational Limited was incorporated on 05-JUN-2020 as a Private company limited by shares registered in Hong Kong. It’s company registration number is: 2949329.

Hong Kong Companies Directory – About TRBHInternational Limited’s information may come from different sources and aggregate fill. All information published on our website are for reference only. If you want to update any information on this page, please use your company’s official email account to contact us. When you give us your information, you do not need to spend any cost. Our goal is to help every business growth. This information may have been updated since the last change,please visit the official website of hong kong companies registry to check the latest results.

Risk Warning: Forex and CFD trading involves a significant risk to your invested capital. Please read and ensure you fully understand our Risk Disclosure.